Total mortality · people with primary hypertension
All angiotensin converting enzyme (ACE) inhibitors showed no clear difference in total mortality compared with all angiotensin receptor blockers (ARBs) (moderate certainty).
1 finding from 1 review
Mortality at day 30 · AKI
Intensive showed no clear difference in mortality at day 30 compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
1 finding from 1 review
Mortality: patients with sepsis · patients with AKI who need CRRT
Intensive showed no clear difference in mortality: patients with sepsis compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
1 finding from 1 review
All‐cause mortality · pulmonary arterial hypertension
Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in mortality compared with placebo, on combination therapy (moderate certainty).
1 finding from 1 review
All‐cause mortality · pulmonary arterial hypertension
Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in mortality compared with ERA (moderate certainty).
1 finding from 1 review
All‐cause mortality · pulmonary arterial hypertension
Group 1 Pulmonary arterial hypertension ‐ PDE5i leads to lower mortality compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality · people with pulmonary hypertension group 2 ‐ 4
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality: patients without sepsis · patients with AKI who need CRRT
Intensive showed no clear difference in mortality: patients without sepsis compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
1 finding from 1 review
All‐cause mortality · people with pulmonary hypertension due to lung disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with pulmonary hypertension due to left‐heart disease
Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Mortality after 30 days post‐randomisation · AKI
Intensive showed no clear difference in mortality after 30 days post‐randomisation compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
1 finding from 1 review
Mortality: patients with AKI not related to surgery · patients with AKI who need CRRT
Intensive showed no clear difference in mortality: patients with AKI not related to surgery compared with less intensive continuous renal replacement therapy (CRRT) (low certainty).
1 finding from 1 review
Mortality: patients with AKI related to cardiac or general surgery · patients with AKI who need CRRT
Intensive leads to lower mortality: patients with AKI related to cardiac or general surgery compared with less intensive continuous renal replacement therapy (CRRT) (high certainty).
1 finding from 1 review
All‐cause mortality · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes all‐cause mortality compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Total mortality · adults with primary hypertension
First‐line angiotensin converting enzyme inhibitor probably leads to lower total mortality compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy showed no clear difference in all‐cause mortality compared with control (low certainty).
1 finding from 1 review
Total mortality Mean duration of 3.8 years · adults 60 years or older with primary hypertension
Antihypertensive drug leads to lower total mortality Mean duration of 3.8 years compared with placebo or no treatment (high certainty).
1 finding from 1 review
Cardiovascular mortality and morbidity Mean duration of 3.7 years · adults 60 years or older with primary hypertension
Antihypertensive drug probably leads to lower cardiovascular mortality and morbidity Mean duration of 3.7 years compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Cerebrovascular mortality + morbidity · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy may leads to lower cerebrovascular mortality + morbidity compared with control (low certainty).
1 finding from 1 review
Cerebrovascular mortality + morbidity · adults 60 years or older with primary hypertension
Antihypertensive drug probably leads to lower cerebrovascular mortality and morbidity Mean duration of 3.7 years compared with placebo or no treatment (moderate certainty).
1 finding from 1 review